logo.jpg
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
16 sept. 2022 08h30 HE | Zylö Therapeutics
Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...